A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: The safety profile of Ad5/3-Δ24 in advance of a phase i clinical trial in ovarian cancer patients

Human Gene Therapy

Volumn 22, Issue 7, 2011, Pages 821-828

  Kim, Kenneth H ^a   Ryan, Michael J ^b   Estep, James E ^b   Miniard, Brock M ^b   Rudge, Thomas L ^b   Peggins, James O ^c   Broadt, Trevor L ^d   Wang, Minghui ^e   Preuss, Meredith A ^e   Siegal, Gene P ^f   Hemminki, Akseli ^g   Harris, Raymond D ^d   Aurigemma, Rosemarie ^c   Curiel, David T ^e   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e University of Alabama at Birmingham   (United States)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CHIMERA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SEROTYPE; SYRIAN HAMSTER; VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; CRICETINAE; DISEASE MODELS, ANIMAL; DNA, VIRAL; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAPERITONEAL; MESOCRICETUS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; SEROTYPING; TISSUE DISTRIBUTION; VIRUS REPLICATION;

ANIMALIA; MESOCRICETUS AURATUS;

EID: 79960375953     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.180     Document Type: Article

References (26)

1. Bauerschmitz, G.J., Lam, J.T., Kanerva, A., et al. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62, 1266-1270. (Pubitemid 34407775)
2. Dmitriev, I., Krasnykh, V., Miller, C.R., et al. (1998). An adeno-virus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and ad-enovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713. (Pubitemid 28520834)
3. Douglas, J.T., Kim, M., Sumerel, L.A., et al. (2001). Efficient on-colysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 61, 813-817. (Pubitemid 32174383)
4. Fueyo, J., Gomez-Manzano, C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12. (Pubitemid 30066345)
5. Erratum in Oncogene 19, 5038.
6. Guse, K., Ranki, T., Ala-Opas, M., et al. (2007). Treatment of metastatic renal cancer with capsid-modified oncolytic ade-noviruses. Mol. Cancer Ther. 6, 2728-2736. (Pubitemid 350058153)
7. Heise, C., Hermiston, T., Johnson, L., et al. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat. Med. 6, 1134-1139.
8. Erratum in: Nat. Med. 6, 1412.
9. Jemal, A., Siegel, R., Xu, J., et al. (2010). Cancer statistics, 2010. CA. Cancer J. Clin. 60, 277-300.
10. Kanerva, A., Mikheeva, G.V., Krasnykh, V., et al. (2002a). Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin. Cancer Res. 8, 275-280. (Pubitemid 34101488)
11. Kanerva, A., Wang, M., Bauerschmitz, G.J., et al. (2002b). Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5, 695-704. (Pubitemid 34619062)
12. Kanerva, A., Zinn, K.R., Chaudhuri, T.R., et al. (2003). Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol. Ther. 8, 449-458. (Pubitemid 37167933)
13. Kangasniemi, L., Kiviluoto, T., Kanerva, A., et al. (2006). In-fectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin. Cancer Res. 12, 3137-3144. (Pubitemid 43837362)
14. Kimball, K.J., Preuss, M.A., Barnes, M.N., et al. (2010). A phase I study of a tropism-modified conditionally replicative adeno-virus for recurrent malignant gynecologic diseases. Clin Cancer Res. 6, 5277-5287.
15. Koski, A., Kangasniemi, L., Escutenaire, S., et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 18, 1874-1884.
16. Krasnykh, V., Dmitriev, I., Navarro, J.G., et al. (2000). Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 60, 6784-6787. (Pubitemid 32059138)
17. Lam, J.T., Kanerva, A., Bauerschmitz, G.J., et al. (2004). Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy. J. Gene Med. 6, 1333-1342. (Pubitemid 40287705)
18. Matthews, K., Noker, P.E., Tian, B., et al. (2009). Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin. Cancer Res. 15, 4131-4137.
19. Matthews, K.S., Alvarez, R.D., Curiel, D.T. (2009). Advancements in adenoviral based virotherapy for ovarian cancer. Adv. Drug. Deliv. Rev. 61, 836-841.
20. National Cancer Institute (NCI). (2006). NCI issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available at www.cancer.gov/news center/pressreleases/IPchemotherapyrelease (accessed March 10, 2010).
21. Page, J.G., Tian, B., Schweikart, K., et al. (2007). Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am. J. Obstet. Gy-necol. 196, 389e1-e10.
22. Raki, M., Sarkioja, M., Desmond, R.A., et al. (2008). Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol. Oncol. 108, 166-172. (Pubitemid 350299441)
23. Ranki, T., Sarkioja, M., Hakkarainen, T., et al. (2007). Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int. J. Cancer 121, 165-174. (Pubitemid 46753865)
24. Thomas, M.A., Spencer, J.F., La Regina, M.C., et al. (2006). Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 66, 1270-1276. (Pubitemid 43259903)
25. Vanderkwaak, T.J., Wang, M., Gomez-Navarro, J., et al. (1999). An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74, 227-234. (Pubitemid 29377217)
26. Vasey, P., Shulman, L.N., Campos, S., et al. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted ade-novirus, ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569. (Pubitemid 34260536)